Merck's ERVEBO Vaccine Receives Expanded EU Indication for Children as Young as One Year Old

Strategic Insights -

Merck, known as MSD outside of the United States and Canada, has announced that the European Commission has approved an expanded indication for ERVEBO, a vaccine designed to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus. This approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) received on July 20, 2023, and represents a significant milestone in the ongoing effort to prepare for outbreaks of Zaire ebolavirus. The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

According to Dr. Eliav Barr, senior vice president and head of global clinical development and chief medical officer at Merck Research Laboratories, "Ebola virus disease is severe and potentially life-threatening for both children and adults. The European Commission's expanded approval of ERVEBO for children 1 year of age and older is an important milestone for the prevention of disease caused by Zaire ebolavirus."

The approval of ERVEBO for use in children as young as one year old is a significant step forward in the fight against Zaire ebolavirus, which has been responsible for numerous outbreaks and high fatality rates over the last 20 years. The vaccine has been engineered to be effective against the Zaire ebolavirus strain, with the potential to provide long-term protection against the disease.

Key Takeaways:

  • ERVEBO is a live recombinant viral vaccine designed to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus.
  • The vaccine has been approved for use in children as young as one year old, with the approval following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
  • ERVEBO has been engineered to provide long-term protection against Zaire ebolavirus, with the potential to reduce the risk of transmission and severe disease.
  • The vaccine has been approved in the European Union, United Kingdom, United States, Canada, Switzerland, and 10 countries in Africa.
  • ERVEBO is a live vaccine, which may pose a theoretical risk of transmission of the vaccine virus.

Statistics:

  • Over 500,000 doses of ERVEBO have been delivered to a global Ebola vaccine stockpile, which is managed by the International Coordinating Group on Vaccine Provision.
  • ERVEBO has been tested in over 18,000 participants in clinical trials, with two reports of anaphylaxis and a range of other adverse events.
  • The most commonly reported local and systemic adverse events in clinical trials were injection-site pain, headache, feverishness, muscle pain, and somnolence.

Sources:

  • European Commission press release, "European Commission Approves Expanded Indication for ERVEBO for Active Immunization of Individuals 1 Year of Age or Older to Protect Against Ebola Virus Disease (EVD) Caused by Zaire Ebolavirus" (no date provided).
  • Merck press release, "Merck's ERVEBO Vaccine Receives Expanded EU Indication for Children as Young as One Year Old" (no date provided).
  • European Medicines Agency press release, "CHMP Recommends Approval of ERVEBO for the Prevention of Ebola Virus Disease in Children as Young as One Year Old" (July 20, 2023).